Browsing by author "Stankunaite, Reda"
Now showing items 1-6 of 6
-
Circulating tumour DNA sequencing to determine therapeutic response and identify tumour heterogeneity in patients with paediatric solid tumours.
Stankunaite, R; George, SL; Gallagher, L; Jamal, S; Shaikh, R; et al. (ELSEVIER SCI LTD, 2021-12-18)OBJECTIVE: Clinical diagnostic sequencing of circulating tumour DNA (ctDNA) is well advanced for adult patients, but application to paediatric cancer patients lags behind. METHODS: To address this, we have developed a ... -
Liquid biopsy for children with central nervous system tumours: Clinical integration and technical considerations.
Stankunaite, R; Marshall, LV; Carceller, F; Chesler, L; Hubank, M; et al. (FRONTIERS MEDIA SA, 2022-11-16)Circulating cell-free DNA (cfDNA) analysis has the potential to revolutionise the care of patients with cancer and is already moving towards standard of care in some adult malignancies. Evidence for the utility of cfDNA ... -
Molecular Characterization of Circulating Tumor DNA in Pediatric Rhabdomyosarcoma: A Feasibility Study.
Ruhen, O; Lak, NSM; Stutterheim, J; Danielli, SG; Chicard, M; et al. (LIPPINCOTT WILLIAMS & WILKINS, 2022-10-01)PURPOSE: Rhabdomyosarcomas (RMS) are rare neoplasms affecting children and young adults. Efforts to improve patient survival have been undermined by a lack of suitable disease markers. Plasma circulating tumor DNA (ctDNA) ... -
Molecular profiling of cell free DNA in patients with paediatric solid tumours
Hubank M; Stankunaite, R; Hubank, M (Institute of Cancer Research (University Of London), 2023-05-02)Tumour tissue profiling studies show that a substantial proportion of paediatric cancer patients have potentially actionable alterations and minimally invasive molecular profiling test using cell free DNA (cfDNA) could ... -
Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells.
Berlak, M; Tucker, E; Dorel, M; Winkler, A; McGearey, A; et al. (BMC, 2022-06-10)BACKGROUND: Development of resistance to targeted therapies has tempered initial optimism that precision oncology would improve poor outcomes for cancer patients. Resistance mechanisms, however, can also confer new ... -
Repurposing Vandetanib plus Everolimus for the Treatment of ACVR1-Mutant Diffuse Intrinsic Pontine Glioma.
Carvalho, DM; Richardson, PJ; Olaciregui, N; Stankunaite, R; Lavarino, C; et al. (AMER ASSOC CANCER RESEARCH, 2022-02-01)Somatic mutations in ACVR1 are found in a quarter of children with diffuse intrinsic pontine glioma (DIPG), but there are no ACVR1 inhibitors licensed for the disease. Using an artificial intelligence-based platform to ...